Volume : 11, Issue : 02, February – 2024
Title:
A CASE REPORT ON STEROID INDUCED DIABETIC INTOLERANCE
Authors :
Dr. Sini S G*
Abstract :
Since the advent of glucocorticoid therapy for autoimmune diseases in 1940s, their widespread application has led to the concurrent therapy limiting discovery of many adverse metabolic side effects. Steroid is a biologically active organic compound having immunosuppressive action in living organisms. It can cause a deviation in the blood glucose level of patient. Unanticipated hyper glycemia associated with the initiation of glucocorticoids often leads to prolonged hospital stays, increased risks for infection etc. Glucocorticoids are extensively used in every areas of medicine. Although it is widely prescribed for their anti-inflammatory and immunosuppressive properties. Recently Steroid Induced Diabetes Mellitus (SIDM) has been recognized as severe and important side effect. SIDM is defined as an abnormal increase in blood glucose associated with the use of glucocorticoids in a patient with or without a prior history of Diabetes Mellitus. It is a typical case on steroid induced diabetic intolerance.
Keywords: Diabetes Mellitus, Diabetic intolerance, Steroids
Cite This Article:
Please cite this article in press Dr. Sini S G ., A Case Report On Steroid Induced Diabetic Intolerance , Indo Am. J. P. Sci, 2024; 11 (02).
Number of Downloads : 10
References:
1. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482–2494 2. Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ et al (2017) NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw 15:883–893 3. Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH (2012) Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol 30:3998–4003 4. Basch E, Hesketh PJ, Kris MG, et al. (2011). Antiemetics: American society of clinical oncology clinical practice guideline update. J Oncol Pract.;7:395–8 5. Herrington JD, Jaskiewicz AD, Song J (2008) Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112:2080–2087 6. Griffin AM, Butow PN, Coates AS et al (1996) On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189–195